Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Glaukos Corp (Glaukos) is an ophthalmic medical technology and pharmaceutical company. It develops and commercializes novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company's activities include the development of micro-invasive glaucoma surgery (MIGS) devices and sustained-release drug delivery platforms. Glaukos serves patients with chronic eye diseases and provides solutions for eye care professionals to enhance patient care. The company markets its products through a network of distributors in the US, Canada, the UK, Germany, Japan, Australia, and Brazil. Glaukos is headquartered in Aliso Viejo, California, the US.
Headquarters
United States of America
Address
1 Glaukos Way, Aliso Viejo, California, 92656
Website
www.glaukos.com
Telephone
1 949 3679600
No of Employees
1,094
Industry
Medical Equipment
Ticker Symbol & Exchange
GKOS (NYSE)
Revenue (2024)
$507.4M
32.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-28.2%
(2024 vs 2023)
Market Cap*
$8.7B
Net Profit Margin (2024)
XYZ
3.1%
(2024 vs 2023)
* As of and is in US$
Glaukos Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ophthalmic Medical Device | iDose |
| iStent Trabecular Micro-Bypass Stent | iStent infinite |
| iStent inject | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In October, the company received approval from the US Food and Drug Administration for its Epioxa HD / Epioxa for the treatment of keratoconus, a rare, sight-threatening disease. |
| 2025 | Plans/Strategy | In February, the company announced its plans to construct a research, development and manufacturing facility at Cummings Research Park in Huntsville, Alabama, the US. |
| 2024 | Contracts/Agreements | In September, the company signed an exclusive research and license option agreement with Nicox SA to finance NCX 1728 preclinical research activities. |
Competitor Comparison
| Key Parameters | Glaukos Corp | Johnson & Johnson | Novartis AG | Bayer AG | Regeneron Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | Germany | United States of America |
| City | Aliso Viejo | New Brunswick | Basel | Leverkusen | Tarrytown |
| State/Province | California | New Jersey | Basel-Stadt | Nordrhein-Westfalen | New York |
| No. of Employees | 1,094 | 138,200 | 75,267 | 87,757 | 15,410 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas W. Burns | Chairman; Chief Executive Officer | Executive Board | 2021 | 65 |
| Alex R. Thurman | Chief Financial Officer; Senior Vice President | Senior Management | 2022 | 56 |
| Joseph E. Gilliam | Chief Operating Officer; President | Senior Management | 2022 | 50 |
| Jay L. Katz, MD | Chief Medical Officer | Senior Management | 2017 | - |
| Tomas Navratil, Ph.D. | Chief Development Officer | Senior Management | 2022 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer